AI news impact · US stocks
Inovio Pharmaceuticals, Inc. (INO) news impact
On 2026-11-11 Wave Radar's AI rated the news on Inovio Pharmaceuticals, Inc. as neutral (impact score +55%).
Inovio reported Q3 results and is preparing the commercial launch of its first approved product, VOCERYQ, following FDA accelerated approval for RRP.
- Direction
- Neutral
- Impact score
- +55%
- Confidence
- 85%
- Headlines read
- 4
- Date
- 2026-11-11
AI assessment
The transition to commercial stage with VOCERYQ marks a key milestone, offering new revenue potential while quarterly burn remains in focus.
Sector impact
Introduces competitive pressure for peers targeting RRP like Precigen, providing a mild catalyst for the rare disease biotech space.
Headlines the AI read
- Inovio (INO) Q3 2026 Earnings Call Transcript Yahoo Finance/INO · 2026-11-11
- Inovio Pharmaceuticals Q3 Earnings Call Highlights Yahoo Finance/INO · 2026-11-11
- Inovio: Q3 Earnings Snapshot Yahoo Finance/INO · 2026-11-10
- Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect? Yahoo Finance/INO · 2026-11-02
More on Inovio Pharmaceuticals, Inc.
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.